- Home
- RNA vs ADMA Comparison
RNA vs ADMA Comparison
Compare RNA & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNA
- ADMA
- Stock Information
- Founded
- RNA 2012
- ADMA 2004
- Country
- RNA United States
- ADMA United States
- Employees
- RNA N/A
- ADMA N/A
- Industry
- RNA Biotechnology: Pharmaceutical Preparations
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RNA Health Care
- ADMA Health Care
- Exchange
- RNA Nasdaq
- ADMA Nasdaq
- Market Cap
- RNA 4.0B
- ADMA 3.7B
- IPO Year
- RNA 2020
- ADMA N/A
- Fundamental
- Price
- RNA $48.44
- ADMA $14.50
- Analyst Decision
- RNA Strong Buy
- ADMA Strong Buy
- Analyst Count
- RNA 17
- ADMA 3
- Target Price
- RNA $69.53
- ADMA $27.67
- AVG Volume (30 Days)
- RNA 3.4M
- ADMA 3.4M
- Earning Date
- RNA 11-06-2025
- ADMA 11-06-2025
- Dividend Yield
- RNA N/A
- ADMA N/A
- EPS Growth
- RNA N/A
- ADMA 469.09
- EPS
- RNA N/A
- ADMA 0.85
- Revenue
- RNA $10,729,000.00
- ADMA $474,174,000.00
- Revenue This Year
- RNA N/A
- ADMA $21.17
- Revenue Next Year
- RNA $108.74
- ADMA $26.03
- P/E Ratio
- RNA N/A
- ADMA $17.31
- Revenue Growth
- RNA 1.23
- ADMA 43.58
- 52 Week Low
- RNA $21.51
- ADMA $13.50
- 52 Week High
- RNA $56.00
- ADMA $25.67
- Technical
- Relative Strength Index (RSI)
- RNA 60.32
- ADMA 30.18
- Support Level
- RNA $38.94
- ADMA $14.43
- Resistance Level
- RNA $47.96
- ADMA $15.38
- Average True Range (ATR)
- RNA 2.19
- ADMA 0.48
- MACD
- RNA 0.54
- ADMA -0.10
- Stochastic Oscillator
- RNA 97.67
- ADMA 3.57
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.